Passing a federal law to stem rising drug prices would have a modest effect on the U.S. prescription drug pipeline, a new CBO analysis finds.

Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline

Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in the second, and 34 fewer (-8%), in the third, congressional budget analysts say.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content